Welcome to our dedicated page for A SPAC III Acqsn SEC filings (Ticker: ASPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
A SPAC III Acquisition Corp. filings document the regulatory record of a British Virgin Islands blank-check company with Nasdaq-listed units, Class A ordinary shares and rights. Its disclosures cover 8-K material events, proxy and governance matters, shareholder votes, capital-structure changes, sponsor share arrangements and SPAC security terms.
The filing record includes amendments to the company’s memorandum and articles of association, business-combination deadline-extension matters, unregistered equity issuance disclosure, PFIC annual statement materials and exhibits related to formal corporate actions.
A SPAC III Acquisition Corp. (ASPC) amended its charter to extend the deadline to complete a business combination by 12 months, moving from November 12, 2025 to November 12, 2026, effective October 27, 2025.
Shareholders approved the charter amendment at an extraordinary general meeting on October 27, 2025. Votes cast were 4,178,733 FOR and 2,934,951 AGAINST. As of the October 6, 2025 record date, 8,055,000 ordinary shares were outstanding, and 7,113,684 shares were voted, representing 88.31% of outstanding shares.
An aggregate of 5,717,419 ordinary shares were tendered for redemption in connection with the meeting. Separately, on October 25, 2025, the Sponsor agreed to transfer 100,000 Class B ordinary shares after the consummation of an initial business combination to an unaffiliated third party in exchange for that party voting 621,084 Class A ordinary shares in favor of the amendment.
ASPC seeks shareholder approval to amend its charter to extend the deadline to complete an initial business combination from November 12, 2025 to November 12, 2026. The Board has unanimously approved a proposed merger with Bioserica International Limited that would (i) reincorporate the company through a merger with a Purchaser and (ii) make Bioserica a wholly-owned subsidiary of the surviving entity. Public shareholders may elect cash redemption based on the Trust Account balance; an illustrative per-share redemption price was approximately $10.38 as of October 6, 2025. The Sponsor owns 1,500,000 Founder Shares and 285,000 Private Placement Units; if no combination occurs by the Extended Termination Date those holdings would become worthless. The Sponsor currently does not plan to contribute additional funds to the Trust Account. The proposal does not add funds to the Trust Account; approval would give the company more time to complete the Business Combination but may reduce per-share trust proceeds available to redeeming public shareholders.
The preliminary proxy describes a proposed Charter Amendment to extend ASPC's combination deadline from November 12, 2025 to November 12, 2026 and related shareholder votes. It discloses a May 23, 2025 Merger Agreement to combine with Bioserica via a series of reincorporation and acquisition mergers, which the board unanimously approved and will be submitted to shareholders for separate approval. Public shareholders may redeem for a cash amount equal to the trust account balance (less up to $100,000 for dissolution expenses) divided by outstanding public shares; if the company winds up, rights to receive post-combination ordinary shares will expire worthless. The proxy notes the Sponsor does not currently intend to fund an extension, officers and insiders may not be reimbursed for excess out-of-pocket expenses if no combination occurs, founder/private placement shares remain locked until a business combination, and national security (CFIUS) and other regulatory risks may limit target availability.